Britt Meelby Jensen

CEO and General Manager Dako. 21 hours agoBritt Meelby Jensen was CEO of Malmö Sweden-based medical device developer Altos Medical from 2019 until March 1 stepping down after the laryngectomy care companys acquisition by Humlebaek.

Kreuzfahrt Stern De

Ambus nye topchef Britt Meelby Jensen erkender at syv nedjusteringer på tre år har tæret på tilliden til selskabet.

. Chief Executive Officer Atos Medical. On March 1 2022 the former Zealand Pharma CEO steps back from the position in Atos Medical which Coloplast acquired for EUR 22bn in November. The Board of Directors of Ambu AS has appointed Britt Meelby Jensen as new Chief Executive Officer.

From 2019 to early 2022 Britt Meelby Jensen served as CEO of Atos Medical AB. From 2019 Britt Meelby Jensen served as CEO of Swedish Atos Medical until she led the sale of the company to Coloplast in early 2022. Britt Meelby Jensen has served as CEO of Atos Medical since 2019 after serving as CEO of Zealand Pharma AS and Dako AS previously.

Direktør i Ambu er den rette kandidat til at genskabe tilliden til medicoselskabet efter blandt andet syv nedjusteringer på tre år. Britt Meelby Jensen København Hovedstaden Danmark500 forbindelser Tilmeld dig for at oprette forbindelse Artikler af Britt Meelby Interview with Kristian Villumsen CEO of. Furthermore she has in-depth knowledge and understanding of the Novo Group having held various leadership positions between 2002-2013 at Novo Nordisk AS.

View Britt Meelby Jensens professional profile on Relationship Science the database of decision makers. She has also previously served in a similar role as CEO of Swedish Atos Medical until the company was sold off to Coloplast in early 2022. Sådan lyder vurderingen fra flere analytikere ifølge Finans.

International Marketing Management Copenhagen Business School 2000. Det vil hun rette op på Den erfarne topchef Britt Meelby Jensen skal nu vende udviklingen i det pressede medicoselskab Ambu. Kompetencer og særlige opgaver i bestyrelsen.

Since Juan Jose Gonzalez joined as CEO in 2019 Ambu has made. Jensen previously was Chief Executive Officer at Zealand Pharma A Chief Executive Officer at Atos Medical AB Vice President General Manager at Dako Denmark ApS and Chief Executive Officer for. For sin rolle i Atos.

På valg i 2024. Genvalgt senest i 2021. Press Releases One News Page.

Britt Meelby Jensen has served as board member of The Board of Directors of Ambu AS has appointed Britt Meelby Jensen as new Chief Executive Officer CEO. Facts Britt Meelby Jensen Born. Britt Meelby Jensen has served as board member of Ambu since 2019 a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will.

After three years at the front of Swedish medtech company Atos Medical Britt Meelby Jensen has set the date for when she will leave the company a press release announces. Member of the Board Hempel Foundation Hempel Invest AS. Britt Meelby Jensen has served as board member of Ambu since 2019 a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the.

President and CEO Zealand Pharma AS. 1 day agoA seasoned life science CEO Britt Meelby Jensen born in 1973 has more than 20 years of experience from the life science industry. In connection with selling the company to Coloplast Britt decided to step down as CEO to continue as an adviser as of March 2022.

From 2019 Britt Meelby Jensen served as CEO of Swedish Atos. Hun har en del kredit i markedet bla. Competencies and special tasks on the Board.

Member of the Board Ambu AS. 1 day agoBritt Meelby Jensen born in 1973 has more than 20 years of experience from the life science industry. 4 hours agoBritt Meelby Jensen der torsdag blev udpeget til ny adm.

From 2015 to 2019 Britt Meelby Jensen was CEO of Zealand Pharma. MBA Solvay Business School Brussels 1998 MSc Copenhagen Business School 2000. The Board of Directors of Ambu AS has appointed Britt Meelby Jensen as new Chief Executive Officer CEO.

Member of the Novo Advisory Group Novo Holdings. Britt Meelby Jensen has served as board member of Ambu since 2019 a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. From 2015 to 2019 Britt Meelby Jensen was President and CEO of Zealand Pharma AS.

Britt Meelby Jensen is Vice President at Agilent Technologies Inc. Britt Meelby Jensen var den oplagte kandidat. From 2019 Britt Meelby Jensen served as CEO of Swedish Atos Medical until she led the sale.

International Marketing Management Copenhagen Business School 2000 MBA Economics Solvay Business. Britt Meelby Jensen is on the board of Novo Holdings An and 6 other companies. Britt Meelby Jensen Work Experience and Education.

Fra 2015-2019 var Britt Meelby Jensen administrerende direktør for det børsnoterede biotekselskab Zealand Pharma og hun har tidligere også stået i spidsen for Dako og har haft ledende stillinger i Novo Nordisk. 1 day agoHis place at the helm will be taken over by Britt Meelby Jensen who has been a board member of Ambu since 2019 a position she leaves as part of the executive reshuffle. A seasoned life science CEO Britt Meelby Jensen born in 1973 has more than 20 years of experience from the life science industry.

Britt Meelby Jensen Hempel Foundation